• Deerfield Management, Khosla Ventures, and Sofinnova Partners co-lead Series A fundraise for Excelsior Sciences to accelerate drug discovery and clinical development while supporting pharma reshoring.

NEW YORK–(BUSINESS WIRE)–Excelsior Sciences, a company developing a new form of chemistry that machines can do and AI can use to enable closed-loop drug discovery, today announced it has raised $95 million to accelerate its mission to reinvent the process of discovering and manufacturing small molecules.

The financing includes a $70 million Series A, co-led by Deerfield Management, Khosla Ventures, and Sofinnova Partners, as well as a $25 million grant from New York’s Empire State Development. Other participants include Cornucopian Capital, Eli Lilly and Company, Illinois Ventures, and the leading academic institution, MIT.

A Novel Approach for Small Molecule Science

Small molecules, the class of chemical matter primarily built from carbon-carbon bonds, perform countless essential functions in our lives: they are central to our life-saving drugs, manufacturing materials, veterinary and agricultural products, and much more. While AI has the potential to transform these fields, it requires the ability to make and test new small molecules in multiple assays fast enough to feed data-hungry algorithms.

Earlier attempts to automate chemistry have failed because they replicate the traditional artisanal approach to chemical synthesis. By contrast, Excelsior Sciences has created a proprietary form of chemistry that machines can do. At the heart of this innovation are smart bloccs—automated synthesis-friendly chemical building blocks that enable iterative carbon–carbon bond formation. Smart bloccs serve as a modular chemical “language,” allowing AI to derive novel insights and guide discovery in closed-loop learning systems.

“Drug discovery and manufacturing are at a crossroads in the West. To stay competitive, we must discover and develop better medicines—faster. This can only be achieved through automated synthesis platforms capable of rapidly producing purified compounds and testing them across multiple assays simultaneously—generating the rich data AI needs to cut years off traditional discovery timelines,” said Michael Foley, PhD, co-founder and CEO of Excelsior Sciences. “Our proprietary smart bloccs platform is the first system to seamlessly integrate discovery and scale-up chemistry, enabling the reshoring of drug discovery and manufacturing. We are starting with drug discovery but will work across multiple sectors.”

The Reshoring Imperative

Excelsior’s launch comes at a pivotal time for the pharmaceutical industry, which is under pressure to secure supply chains and reshore more of its discovery and manufacturing capabilities. The United States’ overreliance on offshoring for the discovery and manufacturing of the nation’s drug supply represents a major strategic vulnerability—one the pharma industry is committing upwards of $250 billion to address.

Excelsior Sciences aims to make reshoring affordable for both discovery and manufacturing, providing strategic immunity to nations whose pharma supply chains are vulnerable to sudden geopolitical shifts.

“The idea that sparked Excelsior arose via the company-building relationship Deerfield cultivated with Dr. Marty Burke, whose lab at the University of Illinois discovered and patented the insights that power the smart blocc technology,” said Jim Flynn, Managing Partner at Deerfield. “We view Excelsior’s applications to drug discovery and manufacturing as transformational, and we are pleased to have attracted such strong syndicate partners to advance what we have begun.”

Building the Future of AI-powered Chemistry

This Series A financing will support Excelsior as it scales its smart bloccs platform and demonstrates its ability to revolutionize the discovery and manufacture of small molecules. Excelsior Sciences will also invest in its internal pipeline and build partnerships across a range of industry sectors, including therapeutics and materials science.

“Everyone’s talking about AI-designed drugs, but they cannot become a reality without scalable chemistry. Excelsior is the missing piece. They’ve built the right chemistry for the AI era, where design, synthesis, and testing happen in a closed loop. It’s turning theory into tangible molecules and real medicine. That’s why we backed this exceptional team as part of the Sofinnova Digital Medicine strategy,” said Edward Kliphuis, Partner at Sofinnova Partners.

“Excelsior is closing the gap between what AI can model in theory and what chemistry can make in the real world,” said Nessan Bermingham of Khosla Ventures. “Being able to manufacture small molecules this way opens the door to breakthroughs in new medicines and materials science, and it’s a critically strategic capability to build here in the U.S.”

Empire State Development President, CEO and Commissioner Hope Knight said, “Excelsior Sciences exemplifies how New York continues to attract companies redefining the frontiers of life sciences. Their technology will help address one of the most pressing challenges in American pharmaceutical manufacturing—securing domestic drug supply chains—while establishing our state as a leader in AI-powered chemistry and advanced manufacturing. Empire State Development is proud to support their work as they help shape the future of scientific discovery and production in New York.”

Spun out of Deerfield Management and housed in custom-built laboratory space at Cure in New York City, Excelsior is co-founded by Michael Foley, PhD, Marty Burke, MD, PhD, Bartosz Grzybowski, PhD, and Jana Jensen, PhD, MBA, reflecting the company’s marriage of AI and chemistry.

Organizations, institutions or researchers wishing to register interest in becoming an Excelsior Sciences partner should contact the team at: partnering@excelsiorsci.com.

For media inquiries, please contact the press office (details below).

About Excelsior Sciences

Excelsior Sciences is revolutionizing small molecule innovation. The company is developing a new form of chemistry that machines can do and AI can use to accelerate the discovery and manufacture of small molecules. The company’s unique smart blocc approach quickly creates molecular solutions from automated synthesis-friendly, function-infused, and AI-readable building blocks. These smart bloccs serve as tokens in a modular chemical “language” that enables AI to accelerate discovery and manufacturing, derive novel insights, and define new functional frontiers for an array of industries and applications.

Excelsior Sciences is the only company built on a proven, published track record of making real-world advances in multiple fields using automated small molecule synthesis coupled with AI, with the goal to spark an innovation renaissance of safer, more effective, and more sustainable solutions to human and planetary challenges. For more information, please visit: excelsiorsci.com.

About Empire State Development

Empire State Development is New York’s chief economic development agency, and promotes business growth, job creation, and greater economic opportunity throughout the state. With offices in each of the state’s 10 regions, ESD oversees the Regional Economic Development Councils, supports broadband equity through the ConnectALL office, and is growing the workforce of tomorrow through the Office of Strategic Workforce Development. The agency engages with emerging and next generation industries like clean energy and semiconductor manufacturing looking to grow in New York State, operates a network of assistance centers to help small businesses grow and succeed, and promotes the state’s world class tourism destinations through I LOVE NY. For more information, please visit esd.ny.gov, and connect with ESD on LinkedIn, Facebook and X.

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.

Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners manages over €4 billion in assets. For more information, please visit: sofinnovapartners.com.

About Khosla Ventures

Khosla Ventures is a venture capital firm focused on investments in artificial intelligence, financial services, healthcare, consumer, enterprise, and sustainability. It is known for making early capital investments in startups such as OpenAI, Guardant Health, Instacart, Affirm, DoorDash, and Block.

About Deerfield Management

Deerfield is an investment management firm committed to advancing healthcare through investment, intelligence, and philanthropy. The Firm works across the healthcare ecosystem to connect people, capital, ideas and technology in bold, collaborative and inclusive ways. For more information, please visit www.deerfield.com.

Contacts

Media Contact
excelsiorsciences@yourstorypr.com

(c)2025 Business Wire, Inc., All rights reserved.